Browse drugs

…. For HCC-specific mortality, higher risks were associated with Lenvatinib (aHR 9.04; 95%CI 3.36-24.3; p<0.001), Sorafenib (aHR 5.82; 95%C…

…59/81 (72.8%) (AO)/43/327 (13.1%) and 55/327 (16.8%) (NRI) with adalimumab. Initial non-responders/incomplete responders benefited from sw…

…ation - 43% (9/21) on a DOAC, 48% (10/21) on LMWH, 9% (2/21) on warfarin. 67% (6/9) were discharged on their original DOAC and 50% (1/2)…

…IBD patients in stable remission on combination therapy with IV IFX and TP can be safely switched to SC IFX without the need for co…

…Introduction Elafibranor (ELA) led to significant biochemical improvements in patients w…

…Introduction Infliximab (IFX) improves outcomes in Inflammatory Bowel Disease; however …

…GQS ratings favoured ChatGPT o4-mini, significantly higher than Gemini 2.5 flash and DeepSeek-R1, but comparable to the resident (all p>0.05).Co…

…I) for all-cause mortality were significant for each biomarker: NT-proBNP 1.35 (1.26-1.44); hs-cTnT 1.75 (1.48-2.07); hs-cTnI 1.33 (1.24-…

…Introduction Anthracycline chemotherapies are broad-spectrum anticancer agents, essential …

…nation treatment with mycophenolate and rituximab (MMF-RTX) vs. rituximab monotherapy (RTX) in a single-center cohort of patients affecte…

…up D1) versus adrenalized bupivacaine 0.5%, dexamethasone 4 mg- dexmedetomidine 1.33 µg/kg (group D2). We hypothesized that the D2 group would …

…I 1.27 to 1.71 vs glipizide and HR 1.22, 95% CI 1.05 to 1.42 vs glimepiride). In contrast, the risk of kidney complications was modestly in…